<p>n, number of studies; unknown, including study populations in which the race was mixed or unclear; secondary, including secondary and therapy-related AML; OR, odds ratio; CI, confidence interval; <i>P</i>, <i>P</i> value.</p
<p>Main results of pooled odds ratios (ORs) with confidence interval (CI) in the meta-analysis.</p
<p>P-values for ORs; <i>Ph</i> values of Q-test for heterogeneity test; I<sup>2</sup> refers to the ...
<p>M1: homozygote comparison; M2: heterozygote comparison; M3: dominant model; M4: recessive model; ...
a<p>studies with Caucasian samples were included; <sup>b</sup>studies with Asian samples were includ...
1<p>all summary ORs were calculated using fixed-effects models. In the case of significant heterogen...
<p>AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; CML, chronic myeloid leukaemia; CLL...
<p>N: number of studies included; OR: odds ratio; Ph: p value for heterogeneity; BC: breast cancer; ...
<p>NO: involved studies' number; <i>Gln Lys VS</i>.LysLys: Heterozygote comparison; GlnGln <i>vs</i>...
<p>The center of each square represents the OR, the area of the square is the number of sample and t...
<p>The circles and horizontal lines show the accumulation of estimates as results from each study we...
1<p>all summary ORs were calculated using fixed-effects models. In the case of significant heterogen...
<p>N: number of studies included; OR: odds ratio; P<sub>h</sub>: p value for heterogeneity; BC: brea...
<p>Direction: RA is risk allele. The odds ratio (OR) is presented for the risk allele, compared with...
1<p>All summary ORs were calculated using fixed-effects models. In the case of significant heterogen...
<p>*The Q statistic was used to estimate heterogeneity, and a <i>P</i>≤0.10 was considered statistic...
<p>Main results of pooled odds ratios (ORs) with confidence interval (CI) in the meta-analysis.</p
<p>P-values for ORs; <i>Ph</i> values of Q-test for heterogeneity test; I<sup>2</sup> refers to the ...
<p>M1: homozygote comparison; M2: heterozygote comparison; M3: dominant model; M4: recessive model; ...
a<p>studies with Caucasian samples were included; <sup>b</sup>studies with Asian samples were includ...
1<p>all summary ORs were calculated using fixed-effects models. In the case of significant heterogen...
<p>AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; CML, chronic myeloid leukaemia; CLL...
<p>N: number of studies included; OR: odds ratio; Ph: p value for heterogeneity; BC: breast cancer; ...
<p>NO: involved studies' number; <i>Gln Lys VS</i>.LysLys: Heterozygote comparison; GlnGln <i>vs</i>...
<p>The center of each square represents the OR, the area of the square is the number of sample and t...
<p>The circles and horizontal lines show the accumulation of estimates as results from each study we...
1<p>all summary ORs were calculated using fixed-effects models. In the case of significant heterogen...
<p>N: number of studies included; OR: odds ratio; P<sub>h</sub>: p value for heterogeneity; BC: brea...
<p>Direction: RA is risk allele. The odds ratio (OR) is presented for the risk allele, compared with...
1<p>All summary ORs were calculated using fixed-effects models. In the case of significant heterogen...
<p>*The Q statistic was used to estimate heterogeneity, and a <i>P</i>≤0.10 was considered statistic...
<p>Main results of pooled odds ratios (ORs) with confidence interval (CI) in the meta-analysis.</p
<p>P-values for ORs; <i>Ph</i> values of Q-test for heterogeneity test; I<sup>2</sup> refers to the ...
<p>M1: homozygote comparison; M2: heterozygote comparison; M3: dominant model; M4: recessive model; ...
DOI
Add to ORKG